Andecaliximab
- CAS No.
- 1518996-49-0
- Chemical Name:
- Andecaliximab
- Synonyms
- GS-5745;Andecaliximab;Research Grade Andecaliximab;Research Grade Andecaliximab(DHD06801)
- CBNumber:
- CB68080925
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 571045EIM4 |
Andecaliximab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0621475 | Andecaliximab 98.57% | 1518996-49-0 | 1mg | $325 | 2026-06-04 | Buy |
| ChemScene | CS-0621475 | Andecaliximab 98.57% | 1518996-49-0 | 5mg | $845 | 2026-06-04 | Buy |
| ChemScene | CS-0621475 | Andecaliximab 98.57% | 1518996-49-0 | 10mg | $1354 | 2026-06-04 | Buy |
| ChemScene | CS-0621475 | Andecaliximab 98.57% | 1518996-49-0 | 25mg | $2492 | 2026-06-04 | Buy |
| Biorbyt Ltd | orb1980587 | Andecaliximab Antibody >95% | 1518996-49-0 | 1mg | $290 | 2026-05-06 | Buy |
Andecaliximab Chemical Properties,Uses,Production
Uses
Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF)[1][2].
in vivo
Andecaliximab improves T-cell receptor (TCR) diversity (decreased clonality) within tumor-infiltrating T-cell[1]. Andecaliximab (20 mg/kg; i.p. once) shows the antifibrotic efficacy in a humanized NSG mouse model of idiopathic pulmonary fibrosis[2].
| Animal Model: | Humanized nonobese diabetic, SCID, IL-2 receptor g (NSG) mouse model of IPF[2] |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneal injection; 20 mg/kg, once a week for once |
| Result: | Decreased SMAD2 phosphorylation and increased surfactant protein C. Reduced MMP9+ cells, including MMP9+, CCR10+ and MMP9+CD45- and EpCAM+CCR10+ subpopulations. |
References
[1] Andrew E. Greenstein, et al. Effect of andecaliximab (anti-MMP9) on proteolysis of IL-7 in vitro, TCR diversity in mice, and serum IL-7 in gastric cancer patients in combination with chemotherapy. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium.
[2] Espindola MS, et al. Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 Feb 15;203(4):458-470. DOI:10.1164/rccm.201910-1977OC
Andecaliximab Preparation Products And Raw materials
Raw materials
Preparation Products
Andecaliximab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
